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Abstract: The “antibiotic era”, characterized by the overuse and misuse of antibiotics, over the last
half-century has culminated in the present critical “era of resistance”. The treatment of bacterial infections is challenging because of a decline in the current arsenal of useful antibiotics and the slow
rate of new drug development. The discovery of a new gene (mcr-1) in 2015, which enables bacteria
to be highly resistant to polymyxins (such as colistin), the last line of antibiotic defence left, heralds a
new level of concern as this gene is susceptible to horizontal gene transfer, with alarming potential to
be spread between different bacterial populations, suggesting that the progression from “extensive
drug resistance” to “pan-drug resistance” may be inevitable. Clearly there is a need for the development of novel classes of anti-bacterial agents capable of killing bacteria through mechanisms that are
different to those of the known classes of antibiotics. 1,10-phenanthroline (phen) is a heterocyclic organic compound which exerts in vitro antimicrobial activity against a broad-spectrum of bacteria. The
antimicrobial activity of phen can be significantly modulated by modifying its structure. The development of metal-phen complexes offers the medicinal chemist an opportunity to expand such structural diversity by controlling the geometry and varying the oxidation states of the metal centre, with
the inclusion of appropriate auxiliary ligands in the structure, offering the opportunity to target different biochemical pathways in bacteria. In this review, we summarize what is currently known about
the antibacterial capability of metal-phen complexes and their mechanisms of action.

Keywords: 1,10-phenanthroline, metal complexes, antibacterial activity, antibiotic resistance, alternative therapeutics.
INTRODUCTION
The discovery of antibiotics in 1939 and 1940 was an
important historical advance in medicine for establishing a
pivotal role in the control of untreatable and fatal infectious
diseases [1]. The “antibiotic era” has been marked by the
introduction of a myriad of new antimicrobials with the almost immediate subsequent emergence of resistance to those
drugs [2]. The sequence of events, characterized by the overuse and misuse of antibiotics, over the last half-century has
led to the present critical “era of resistance” [3]. Bacterial
resistance to antibiotics has evolved and now impacts significantly on public health, responsible for high rates of mortality and morbidity globally [4]. Over 13 million deaths
occur worldwide as a result of the emergence of new

infectious diseases and the re-emergence of diseases caused
by multidrug resistant (MDR) strains of bacteria [3]. The
development and spread of antimicrobial resistance is related
to (i) a lack of public knowledge about antibiotics causing
human overuse/misuse of antibiotics and unnatural selective
pressure on bacteria, (ii) misuse of antibiotics in animal feed
stocks associated with food production, (iii) natural process
of evolution of bacterial resistance to antibiotics and (iv) a
diminished interest in the development of antibiotics within
the pharmaceutical industry [1, 5]. The onset of the “era of
resistance” has seen antibacterial drugs become less effective
or even ineffective [6]. Furthermore, therapeutic options for
the treatment of infections have become limited, leading
frequently to recurrent infections, treatment failure and increase of morbidity and mortality, resulting in a global health
emergency [1].

*Address correspondence to this author at the College of Sciences and
Health, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland; Tel:
+353 1 4024585; Fax: +353 1 402 4998; E-mail: michael.devereux@dit.ie

The big challenge for public health is the development
and/or implementation of effective strategies to decrease the
emergence and spread of antimicrobial resistance [1]. The
magnitude of the problem worldwide and the impact on hu-
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man health and on the costs for the health-care sector are
worrying. Infection by drug-resistant bacteria requires the
administration of high doses of antibiotics, resulting in
higher drug toxicity, longer hospital stays and higher mortality [7]. Because of this, the annual impact of resistant infections is estimated to be US$ 21 to 34 billion in excess health
care costs and US$ 8 million additional hospital days in the
United States and over €1.6 to 2.5 billion additional hospital
days in the European Union [5, 6]. Bacteria are responsible
for approximately 90% of all hospital acquired infections,
with immuno-compromised patients being more susceptible
to serious infections, with higher mortality rates than people
with healthy immune systems. The risk of fatality associated
with infections caused by resistant bacteria as compared to
antibiotic sensitive bacteria is much higher. Furthermore, in
most cases of acquired infections involving resistant bacteria
the risk of fatality is exacerbated by prolonged bacterial exposure as a result of delayed or a lack of an appropriate therapy, and not just because of issues associated with any increased in the virulence of the organism [1].
The microorganisms that are mainly involved in the resistance process are called the ESKAPE pathogens - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and
enterobacteriaceae - emphasizing their capacity to “escape”
from common antibacterial treatments [4]. The pathogens
that present the greatest challenges are the multidrug resistance (MDR) and extensively drug resistant (XDR) strains.
MDR strains are defined when they are non-susceptible to
three or more antimicrobial classes, while XDR strains are
non-susceptible to all antimicrobials [4]. Of particular concern are multi- and methicillin-resistant S. aureus (MRSA),
vancomycin-resistant Enterococcus (VRE), P. aeruginosa,
Escherichia coli, Mycobacterium tuberculosis and K. pneumoniae producing extended spectrum β-lactamases (ESBL)
and carbapenemases [1].
Bacteria can be intrinsically resistant to therapeutic
agents and it happens through inherent (natural) resistant.
Otherwise, bacteria can be multidrug resistant and it occurs
when they are transformed through the acquisition of new
genetic material from other resistant organisms. Normally
this process is called horizontal gene transfer (HGT) and it
is performed by bacterial conjugation, transduction, transformation or biofilm formation to spread drug resistance
[7]. Transposons in bacteria can facilitate the direct or indirect transfer and incorporation of drug resistance genes into
the host's genome or plasmids. HGT has recently been reported as multidrug resistance in bacteria can also be
caused by chromosomal mutations and the regulation of
resistant genes. Mechanisms of this type can be classified
into: (i) inactivation or modification of drugs; (ii) alteration
of a target site of antibiotics (it is found that many bacteria
are resistant to antibiotics through this mechanism); (iii)
acquisition of alternative metabolic pathways to those inhibited by antimicrobials; (iv) decreasing drug permeability
of drugs across the cell membrane before they can reach
their target sites and exert their effects on bacteria; (v) enzymatic modification or degradation of the antimicrobial
agents; (vi) over-expression of the drug target; and (vii)
increasing the active efflux pumps that pump out or extrude
antibiotics from the cell [1, 7, 8].
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Implications of Biofilms
It is a particular concern when bacteria become resistant
to various antimicrobial agents simultaneously and mainly
when they form biofilms [1]. An estimated 80% of bacterial
infections in humans are caused by biofilms, and the Centers
for Disease Control have declared biofilms to be the most
pressing clinical impediment of the century [9]. Biofilm
formation is particularly problematic with implantable devices such as prosthetic hips, which often require surgical
removal to eliminate the infection. Biofilm formation is a
complex process involving multiple bacterial signaling systems including quorum sensing (QS), nutrient and chemical
signal response, and extra-cellular matrix formation [9]. A
bacterial biofilm is a cooperative community of unicellular
organisms attached to a solid surface or encased in a hydrated matrix of polysaccharide, protein and nucleic acids.
The extracellular polysaccharides (EPS) are an insoluble and
slimy secretion that is released by bacterial cells, encapsulating adjoining cells in a well-organized and structured matrix
capable of assisting in dissemination of nutrients that are
necessary for cell growth, to bind external nutrient molecules
required for cell sustenance and growth, to provide protection from external environmental stresses that includes protection from antibiotics, disinfectants and from dynamic environments [10].
Biofilms are usually formed through several steps (i) the
initial step in biofilm formation is the adherence of bacteria
to a foreign body or biomaterial; (ii) the transformation from
reversible to irreversible attachment is a relatively rapid
process, taking place within a few minutes or less; (iii) bacterial adhesion is mediated by fimbriae, pili, flagella and
extracellular polymeric substance, which form a communication bridge between bacteria and the conditioning films; (iv)
the aggregation and accumulation of adherent bacteria lead
to the formation of multiple cell layers as the biofilm matures, and (v) the last step is the detachment of bacteria from
the biofilm into a planktonic state, which allows them to
initiate a new cycle of biofilm formation [7, 10]. Some hypotheses for drug resistance in biofilms have been reported
in the literature: (i) in biofilms, the penetration of antibiotics
is slow and incomplete resulting in an in-effective response
to antibacterial agent which must diffuse and penetrate into
the bacterial cells; (ii) a concentration gradient of a metabolic substrate or product leads to zones of slow-growing or
non-growing bacteria with less uptake of antimicrobial
agents than in planktonic cells; (iii) an adaptive stress response is expressed by some bacteria to cope with environmental fluctuations, such as temperature change, oxidative
stress or DNA damage; and (iv) a small fraction of bacteria
differentiate into a highly protected persistent state that reduces the susceptibility of their biofilm to antibiotics [11,
12].
The Limitations of Current Therapeutic Strategies
The treatment of bacterial infections is becoming more
difficult because of a decline in the current arsenal of useful
antibiotics, the development of antibiotic resistance and the
slow rate of new drug development [1, 13]. Recent review
articles in Chemistry World by King are highly critical of the
serious underinvestment globally by governments and
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Fig. (1). Typical structures of theβ-lactams (penicillin), Macrolides (erythromycin) and fluoroquinolones (ciprofloxacin).

pharmaceutical companies for the development of new antimicrobial drugs, even though predictions are that the cost
of antimicrobial resistance (AMR) will be 300 million premature deaths and up to $100 trillion lost to the global economy by 2050 [14, 15]. The US market for antibacterials is
dominated by six antibacterials which fall into just three
structural classes, the β-lactams (Rocephin®, Augmentin®),
macrolides (Zithromax®, Biaxin®), and fluoroquinolones
(Cipro®, Levoquin®) (Fig. 1) [16]. This limited number of
structural classes, in combination with ineffective management of drug usage, is at the heart of the cause of the current
“era of resistance” crisis.

There is clearly a requirement for the development of
new antibacterial agents and given the mechanisms associated with resistance in bacteria, there is a need to ensure that
new approaches to drug development involve compounds
that can target bacterial cells in a completely different way to
those associated with the known antibiotics. In this review,
we explore the potential of inorganic medicinal chemistry as
an alternative approach to developing antibacterial therapeutics, with a specific focus on the mechanisms of action of
metal complexes containing 1,10-phenanthroline ligands.

There is also a lack of diversity in the cellular target of
the known antibiotics. Almost all clinically used antibiotics
inhibit DNA, RNA, protein, or cell wall synthesis, and there
are less than twenty-five molecular targets that account for
their activity. The gravity of the crisis is appreciated as we
witness such developments as the resistance against glycopeptide antibiotics, like vancomycin or teicoplanin, being
observed with increasing frequency and resistance emerging
within one year for the recently introduced oxazolidinones.
The discovery of a new gene (mcr-1) in 2015, which enables
bacteria to be highly resistant to polymyxins, such as colistin
(Fig. 2), the last line of antibiotic defence left, heralds a new
level of concern for the “era of resistance” as this gene is
susceptible to horizontal gene transfer, with alarming potential to be spread between different bacterial populations. This
discovery is very significant as it suggests that the progression from extensive drug resistance to pan-drug resistance
may be inevitable [17].

Inorganic medicinal chemistry has a relatively short history as a specific field, beginning in the 1970’s with the discovery and clinical development of the successful anticancer
drug cisplatin [19]. The design and synthesis of coordination
complexes with novel structures and exhibiting biological
activity, such as antimicrobial, anti-inflammatory, antioxidant and anticancer, establishes this exciting field as offering
great potential to improve the quality of life [20]. Inorganic
medicinal chemistry offers an alternative approach to organic
drug development through opportunities for the design of
therapeutics with the ability to target different biochemical
pathways [21]. The development of drugs that incorporate
metal ions into their molecular structure offers the medicinal
chemist an opportunity to exploit structural diversity, vary
oxidation states of the metal and also offer the possibility of
improving the activity of an established organic drug through
its coordination to the metal centre [22, 23]. The antimicrobial capabilities of metals have been known for thousands of
years, with historical applications in water and food preservation (Cu and Ag), agriculture (Cu) and medicine (Ag, Cu,
Hg, Te, Mg and As) [24]. The medicinal use of metals as
antimicrobials remained prevalent until the discovery of the
“cillin” antibiotics in the 1920’s which then saw their applications decline in popularity. Today, the burgeoning threat of
multidrug resistant microbes to public health and the dearth
of new clinically efficacious antibiotics have resulted in a
renaissance in the use of antimicrobially-active metal ions
and their complexes. Interdisciplinary research in the field of
inorganic medicinal chemistry is advancing our knowledge
of metal toxicity and facilitating the design of metalcontaining compounds as effective and targeted antimicrobials

The resistance problem is exacerbated by the statistic that
bacteria in biofilm communities can be up to 1000-fold more
resistant to eradication compared with their planktonic counterparts. Indeed, very few chemical scaffolds have been identified that can inhibit or disperse bacterial biofilms. An illustration of the lack of development of novel antimicrobials is
the fact that only five new compounds have been approved
over the last twelve years [18]. Both, persistence and spread
of antibiotic resistance, in combination with decreased effectiveness and increased toxicity of current antibiotics have
emphasized the urgent need to search alternative sources of
antibacterial substances [1].

INORGANIC MEDICINAL CHEMISTRY
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offering a realistic alternative to antibiotics [25]. We do not
associate the activity of most conventional antibiotics with
the presence of metal ions. However, a number of antibiotics
are known to require coordinated metal ions to function
properly [25]. These include bleomycin (BLM), streptonigrin
(SN), bacitracin and albomycin which depend on coordinated metal ions to maintain proper structure and/or biological function. The term ‘metalloantibiotic’ has been coined to
describe such metal ion dependent antibiotics and they are
known to exert their bioactivities through interactions with a
variety of biomolecules including DNA, RNA, proteins lipids and receptors. More recently, the term ‘metalloantibiotic’
has been applied, more generally, to metal complexes that
exhibit antibacterial capability.
BIOINORGANIC CHEMISTRY OF BACTERIA
An estimated 25% of all proteins in cells require at least
one transition metal ion to ensure function [26], and for the
known structurally characterised enzymes, the transition
elements (as proportions) that have been identified as cofactors are, Zn (9%), Fe (8%), Mn (6%), Cu (1%), Co (1%), Ni
(0.5%), V (<1%), Mo(<1%), W (<1%) [27]. Many metalloenzymes are involved in the regulation of the metabolic
and physiological processes essential for microbial cell
growth and homeostasis [26, 28, 29]. For example, iron is
required for important cellular processes including DNA
replication, central metabolism and respiration, whilst enzymes containing Zn(II) and Mn(II) centres are crucial for
detoxifying reactive oxygen species (ROS) and reactive nitrogen species (RNS) [30]. Stringent control of the homeostasis of transition metal ions is essential for all life forms.
Limiting the availability of these metal ions to the pathogen,
for example through the imposition of nutritional immunity
by infected mammalian host cells, will disrupt homeostasis,
compromise cellular vitality and ultimately kill the organism
[31]. Furthermore, the use of selected chelators to sequester
metal ions has been shown to inhibit the biological function
of metal-dependent proteins in microbes interfering with
microbial nutrition, growth and development, cellular differentiation, adhesion to biotic and abiotic structures as well as
controlling the progression of the in vivo infection [32, 33].

On the other hand, the ability of microbes to scavenge metals
from vital metalloenzymes in host cells is considered an important virulence attribute [34]. Indeed, an important facet of
infectious disease is the relentless contest between host and
pathogen for transition metal ions.
Whilst relatively small quantities of metal ions are required to sustain microbial growth and reproduction, exposure to high concentrations can be devastating. Not surprisingly, the host cell immune system attempts to exploit this
vulnerability by overloading the bacterial cells with excess
metals in their mission to destroy the pathogen [34]. Under
such duress, the microbes deploy a range of resistance
strategies, which includes restricting uptake, extra- and intracellular sequestration, enzymatic detoxification and efflux, in
their defence against metal poisoning [34, 35]. Lemire et al.
[24] categorised the antimicrobial mechanisms of metal toxicity into 5 specific mechanisms fully recognising that these
categories were not confined to specific microbial cells or
metals. An emphasis was also made on the importance of the
molecular interactions and functions for metal toxicity. The
5 proposed mechanisms were a) Protein dysfunction and
impaired enzyme activity due to oxidative protein damage or
exchange of a structural or catalytic metal; b) Production of
reactive oxygen species (ROS) and antioxidant depletion
demonstrated in numerous metal toxicity studies particularly
for iron [36] and copper [37]; c) Impaired cell membrane
function and loss of membrane potential; d) Interference
with nutrient uptake and assimilation which can directly affect gene expression and the microbial signalling mechanisms of quorum sensing and e) Genotoxicity that was demonstrated by catalytic Fenton-type reactions in Fe which was
linked to DNA damage and cell death [38]. The authors further reported that microbiological studies on genotoxicity
have demonstrated toxicity with Mn(II), Cr(VI), Co(II),
Cd(II), Mo(IV), Sb(III) and As(III) but not Ni(II), Cu(II),
Te(IV), Pb(II), Ag(I) and Al(III) [1]. This highlights the fact
that metals have their own unique biochemical mechanisms
of toxicity in microbial cells and they may trigger several of
these proposed mechanisms simultaneously, but further studies on the association between each of these mechanisms and
microbial cellular death processes as the result of metal tox-
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icity are needed at a molecular level. Moreover, further investigation into the precise role of these mechanisms in
metal resistance and biofilm formation is important to understand the potential mode of action of novel inorganic drugs.

lar differentiation, adhesion to biotic and abiotic structures as
well as playing an important role in the in vivo infection progression [48, 49]. The iron chelating proteins, transferrin and
lactoferrin, have evolved in mammalian cells for the acquisition of iron via specific pathways. These naturally occurring
chelators have been shown to have potential to prevent the
growth of microbial pathogens and their proliferation in host
cells [50, 51]. Therefore, synthetic metal chelators, such as
phen, have received substantial attention as therapeutic
agents because of their ability to alter the metabolism and
homeostasis of essential metals such as iron, copper and
zinc. Furthermore, upon sequestration of metal ions the resulting metal-phen complexes are themselves capable of
exerting a biological response in their own right [32]. MacLeod and his co-workers demonstrated the importance of
the chelating ability of phen in 1952 when they showed that
both its 1,7- and 4,7-phenanthroline isomers were inactive
against lactic acid bacteria [52]. Furthermore, the interaction
of phen with DNA appears to be dependent on the availability of metal cations, such as Cu2+ [32].

1,10-PHENANTHROLINE
1,10-phenanthroline (phen) (Fig. 3) is a heterocyclic organic compound which exerts excellent in vitro antimicrobial activity against a broad-spectrum of bacterial and fungal
pathogens [39-42]. The in vitro antibacterial action of phen
has been demonstrated on a range of bacterial species [40,
41, 43-45]. Ostensibly, the antimicrobial activity of phen can
be significantly modulated by modifying its structure by either extending its backbone at the -5,6- position or by the
substitution of the aromatic protons by suitable substituents
(Fig. 4) [44]. Phen, as a π donor, is also known to form
‘charge-transfer’ derivatives with organic and inorganic
groups to yield organic complexes and quaternary salts that
also exhibit significant in-vitro antibacterial activity [29, 46,
47].

In 2008, Soares et al. demonstrated that the cell surface
and secreted molecules of group B Streptococcus (GBS) are
often essential virulence factors involved in the adherence of
the bacteria to host cells or that they are required to suppress
the defense mechanism of hosts. Cleavage of the host extracellular matrix by GBS may be a relevant factor in the
process of bacterial dissemination and/or invasion. These
workers demonstrated that phen, acting as a metallopeptidase
inhibitor, completely inhibited this cleavage. Notably, phen
(0.1 mM) strongly blocked GBS growth as well as its interaction or invasion in human cell lineages. Herein, GBS strain
90356 adhered to and invaded efficiently to the Human Umbilical Vein Endothelial Cells (HUVECs) model. But the
adhesive property of this strain 90356 was significantly inhibited by ~93% and also its intracellular viability (invasion)
in HUVECs was strongly reduced, by ~82%. The authors
presumed that the metallopeptidases assist GBS in deriving
essential nutrients from human proteins in maintaining GBS
metabolic machinery and physiological processes such as
cellular growth [53].
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Fig. (3). Structure of 1,10-phenanthroline (phen) with numbering
for substituents.

The antimicrobial capability of phen is associated with its
properties as a chelator and its ability to sequester metal ions
in biological systems [32]. Chelation activity is the combination of a metal ion with a chemical compound that coordinates the formation of a chelating ring, often used to remove
heavy metals ions. For many microorganisms, phen has the
capability of inhibiting the biological role of metaldependent proteins, interfering with metal acquisition,
bioavailability and metabolism for crucial reactions, disturbing the microbial cell homeostasis and culminating in the
blockage of microbial nutrition, growth, development, cellu-
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In 2015, Tay et al. tested 1,10-phenanthroline-5,6-dione
(phendione) (Fig. 4), as a potentially novel antimicrobial
agent against Enterococcus and it effectively eradicated E.
faecalis biofilms. It was proposed that the antimicrobial ac-
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tivity of phendione appears to be related to its ability to selectively disturb essential metals (Zn2+, Fe2+, Ca2+, Cu2+,
Co2+, Mn2+ and Ni2+) required for bacterial metabolism and
physiological processes. Therefore, chelation of these metal
ions is responsible for the disruption of cellular vitality and
subsequent cell death. In this study, they demonstrated the
ability of phendione to inhibit the growth of E. faecalis in the
presence of excess Zn2+ ions, suggesting that phendione exerts its antimicrobial effects through its ability to chelate
Zn2+[54].
METAL COMPLEXES OF 1,10-PHENANTHROLINE
Historical Perspective
Phen is an avid chelating agent which forms complexes
with a range of metals [55]. Indeed, the biological activity of
phen has been attributed to its ability to sequester trace metals and the resulting metal complexes are believed to be the
actual active species [56]. Metal complexes containing phen
have shown significant potential as broad-spectrum agents
capable of eliciting cytotoxicity towards diseases and infections manifested by cancer, [42, 57] viruses, [58] bacteria
[59] and fungi [60, 61]. Phen, its related organic compounds
and their corresponding metal complexes are known to inhibit the growth of fungal pathogens by damaging their mitochondrial function, uncoupling respiration, causing nonspecific DNA cleavage, disrupting cell division and inducing
gross distortions in fungal cell morphology [61, 62]. In 1969,
Dwyer et al. published their comprehensive, landmark treatise on the in vitro and in vivo antibacterial activities of dicationic Mn(II) Fe(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and
Ru(II) chelates containing phen and substituted phen (Rphen) ligands [43, 44]. The results demonstrated that the
metal chelates were more active than the ‘metal-free’ phen
ligand, against M. tuberculosis, S. aureus, S. pneumonia, C.
Perfringens, E. coli and P. Vulgaris. With the exception of
the anti-tubercular profiles, the antibacterial activity was
largely independent of the type of metal present. These phen
chelates were also shown to be useful clinically as topical
antimicrobials but selected compounds were found to be
ineffective against mice infected with M. tuberculosis, S.
aureus and S. pneumonia, when administered parenterally.
Whereas cationic metal-phen complexes can be bacteriostatic [43] and bactericidal [39] towards many Grampositive bacteria they are less effective against Gramnegative organisms. This activity trend has been explained in
terms of the high polar lipid content of the cell walls of
Gram-negative bacteria and the consequent impact on the
ability of the complexes to reach vital membrane or intracellular sites [43]. In 1970, Cade et al. reported that, in-vitro,
metal complexes of 3,5,6,8- or 3,4,7,8-tetramethyl-phen
(metal = Ni(II), Fe(II), Co(II), Cu(II), Zn(II), Cd(II), Mn(II),
Ru(II)), the metal-free phen hydrochlorides and their quaternary salts were bactericidal to veterinary samples of Erysipelothrix rhusiopathiae and Fusiformis nodosus [63]. Resistant
variants of the bacterium E. rhusiopathiae were not produced after repeated subculture in the presence of the complexes, [Cu(3,4,7,8-tetramethyl-phen)2]X2 (X = benzoate or
acetate). A similar result had been observed for Staphylococcus aureus, M. tuberculosis, E. coli, C. albicans and Trichophyton mentagrophytes in that they develop little resistance
to this type of complex [40, 64]. Based on these results it

Current Topics in Medicinal Chemistry, 2017, Vol. 17, No. 11

1285

was suggested that the complexes offered potential as therapeutics to treat erysipelas in pigs, and that they may also be
beneficial in the treatment of other topical bacterial infections. Furthermore, [Cu(3,4,7,8-tetramethyl-phen)2]X2 (X =
benzoate or acetate) was also shown to be at least as effective as solutions of formalin and dioxyethyl laural ammonium chloride in addressing foot-rot in sheep. Extensive microbiological and pharmacological studies of this class of
phen-chelate led to the clinical investigation of the highly
stable Ni(II) and Fe(II) complexes of the 3,4,7,8-tetramethylphen ligand [40, 64]. These complexes were shown to exhibit a wide spectrum of antimicrobial actions and to produce negligible toxic responses in skin, subcutaneous tissues
and mucous membranes [64]. Preliminary studies had shown
that the complexes were effective in controlling infections
due to clinical isolates of S. aureus. The Ni(II) complex was
as effective as hexachlorophene, when deployed as a preoperative skin preparation, in reducing the incidence of postoperative staphylococcal wound infection. Furthermore, the
Ni(II) complex was also as effective as hexachlorophene in
the prophylaxis of staphylococcal infection in patients undergoing elective obstetric or gynaecological surgery [65].
This complex also controlled secondary infection in adolescents with persistent acne vulgaris.
In 1970, Cade et al. also examined the clinical applications of Mn(II) complexes of 3,4,7,8-tetramethyl-phen as
topical treatments for a variety of skin conditions, including
chronic dermatological infections due to dermatophytes (e.g.
Malassezia furfur, Trichophyton rubrum) or Candida species
[66]. The complexes induced a significant reduction in the
microbial infection in approximately 50% of cases, with infection due to Gram-positive bacteria generally more responsive to treatment than that due to Gram-negative bacteria. No
noteworthy irritation or sensitization of the underlying dermatosis or dermatomycosis was observed, and, furthermore,
significant microbial resistance did not develop.
These early results clearly demonstrated the antibacterial
chemotherapeutic potential of metal complexes of 1,10phenanthroline. The research was performed at a times when
the antibiotic era was at its height and consequently the significance of the results was not embraced by the pharmaceutical sector. More recently there has been a surge in interest
in the antimicrobial applications of metal-based compounds,
with metal complexes incorporating phen ligands prominent,
and it is imperative that we strive to fully understand how
these complexes exert their biological activity and how they
differ from the resistance-prone antibiotics.
BACTERIAL CELL WALL PERMEABILITY
Like all cells bacteria have a cytoplasmic membrane,
consisting of a phospholipid bilayer and proteins, which performs all of the general functions of a cell membrane (eg.
cytoplasm protection, permeability barrier and selective
transport of molecules into and from the cell) but differs
from the cell membrane in eukaryotes as it does not contain
sterols and it comprises a wider variety of fatty acids and a
higher content of phospholipids [67, 68]. Bacteria also differ
from eukaryotes in that they must be able to survive in much
harsher environments and therefore they possess a robust cell
wall which protects their cytoplasmic membrane and pre-
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vents chemical, biological and physical damage to the organism [67]. Gram-positive cells have cell walls composed of a
thick layer of peptidoglycan and also of two types of teichoic
acids inlaid in their structure: wall teichoic acids, which are
coupled to peptidoglycan, and lipoteichoic acids, which are
anchored to the cell membrane. The peptidoglycan layer is
made up of repeating units of the disaccharide N-acetyl glucosamine-N-actyl muramic acid cross-linked by pentapeptide
side chains that play an important role in physical strength
and bacterial shape as well as in cell division, morphological
differentiation and adaptive responses [68, 69]. Teichoic
acids are long anionic polymers that bind cations playing a
role in cation homeostasis. Additionally, networks of metal
cations between wall teichoic acids also influence the rigidity and porosity of the cell wall and profoundly affect the
interactions of bacteria with other cells or molecules [68].
The cell wall in Gram-negative cells does not contain
teichoic acid and they typically have a much thinner peptidoglycan layer covered by an outer membrane [70]. The
outer membrane is a lipid bilayer, a distinguishing feature of
Gram-negative bacteria, as Gram-positive bacteria lack this
structure. It is composed of glycolipids - mainly lipopolysaccharides (LPS), also known as endotoxins responsible for
much of the toxicity of Gram-negative bacteria, and by two
classes of proteins: lipoproteins and β-barrel transmembrane
proteins. LPS molecules bind each other avidly, especially if
cations like Mg++ are present to neutralize the negative
charge of phosphate groups present on the molecule, and
form a non-fluid continuum barrier very effective for hydrophobic molecules. The transmembrane proteins are β sheets
wrapped into cylinders and some of them, such as the porins
(OmpF and OmpC), allow the passive diffusion of small
hydrophilic molecules (i.e. mono- and disaccharides, amino
acids, molecules ~700 Daltons) across the outer membrane
[68, 71, 72]. Due to the limited diameters of passive diffusion channels, bulky molecules (i.e. iron–siderophores and
complex oligosaccharides) are assumed to be taken up exclusively by active transporters [72].
Several classes of molecules can pass across the outer
membrane without accessing the channels of porins, these
include hydrophobic substances such as detergents, uncharged antibiotics, enzymes like nucleases, phosphatases,
kinases, proteases, etc.) [73]. But, in general, porins are the
major outer membrane proteins with important permeability
barrier properties, which define the size exclusion limit for
hydrophilic molecules by limiting the size and the rate of the
passage of the molecules through these channels, restricting
molecules of similar sizes to the diameters of the porin channels [73]. The conception of “exclusion” reflects the probability that these substances are not taken up across the outer
membrane sufficiently to cause physiological effects on
cells, involving semi-selective exclusion of potentially harmful molecules and affording Gram-negative bacteria an advantage in surviving in lethal environments [73]. The size
exclusion molecular properties of the pores in the outer
membrane are typical of Gram-negative bacteria. The Grampositive cell wall is porous and has a high molecular exclusion limit of >100000 g.mol-1. It means that peptidoglycan
structure provides rigidity and protection to the cell, but is
unlikely to be a contributing factor to any limiting of uptake
of molecules [71, 74, 75]. For example, E. coli and S. typhir-
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nuriurn outer membranes are permeable for hydrophilic solutes up to 600 - 800 g.mol-1. However, solutes up to 3000 9000 g.mol-1 can penetrate the outer membrane of P. aeruginosa. And still there is some evidence that the exclusion molecular weight of certain “exotic” Gram-negative bacteria
would be as large as 20000 g.mol-1 [75, 77]. But even the
molecular exclusion limit of P. aeruginosa being larger than
that of E. coli, the outer membrane permeability of P. aeruginosa has been determined to be approximately 8% of that
of E. coli [75, 78]. This is because most of the P. aeruginosa
pores appear to be nonfunctional, restricting the rate of uptake. And low outer membrane permeability along with effective efflux mechanisms is responsible for the high intrinsic antibiotic resistance of P. aeruginosa [71, 75, 78]. Therefore, the presence of the outer membrane, as a very effective
and selective permeability barrier, greatly decreases the permeability to antibacterials, and it is regarded as a key
mechanism of drug resistance (or sensitivity) in many Gramnegative bacteria [70, 79]. For compounds to act as antibacterials it is generally accepted that they must be lipophilic
and be capable of permeating the cell wall and cytoplasmic
membrane of bacteria [80]. Ironically, ionic silver (Ag+) is a
well-known antimicrobial, in its own right, and its activity
has been linked to its ability to bind to bacterial cell surfaces
and interact with proteins involved in cell wall synthesis [81,
82].
CELL WALL PERMEABILITY AND ACTIVITY OF
METAL-PHEN COMPLEXES
Cationic metal ions do not easily cross the cell membrane
of bacteria and in nature uptake of essential metal ions is
achieved by transporter proteins which effectively wrap the
cations up in a hydrophobic blanket. The same effect can be
achieved by complexation with hydrophobic chelating
ligands such as phen. The ability of such phen-based complexes to cross the cell membrane is explained in the context
of Overtone’s concept of cell permeability [83] and
Tweedy’s chelation theory [84]. According to Overtone’s
concept the lipid membrane surrounding the bacterial cell
favors the passage of lipid soluble compounds and such lipid
solubility is considered to be an important factor controlling
antibacterial activity. Tweedy’s chelation theory explains
how, upon complexation, involving membrane-permeable
ligands such as phen, the polarity of the metal ion is reduced
to a significant extent due to (i) overlap of the ligand orbitals
and partial sharing of the positive charge of the metal ion
with donor groups, (ii) delocalisation of π-electrons over the
chelate ring as a whole, leading to an increase in the lipophilicity and lipid membrane penetration capability of the metal
complex. This process can allow phen-based complexes to
penetrate the cell membrane of bacterial cells and once embedded in the cell membrane or inside the cell they can interact with relevant biomolecules in the microorganisms, leading to inhibition of the cell growth and cell death [85, 86].
Cell membrane permeability is a particular problem associated with Gram-negative bacteria. Whereas there has been
some modest success in the development of new drugs to
treat Gram-positive bacteria, the situation obtaining for the
development of drugs for Gram-negative species involves far
less success [87, 88]. This situation is particularly concern-
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ing as there are very few drugs for Gram-negative bacteria in
the development pipeline. In addressing this challenge it has
recently been demonstrated that pre-exposure to silver Ag+1
ions can potentiate the activity of a broad range of antibiotics
against drug-resistant, Gram-negative bacteria by increasing
their cell membrane permeability and thus restoring their
antibiotic susceptibility [89].
Sixty years ago Dwyer and his co-workers demonstrated
the relationship between lipophilicity and antibacterial activity, for phen-complexes, when they demonstrated that the
activity of [Ru(phen)3]2+ against a range of Gram-positive
and Gram-negative bacteria was significantly improved
through the introduction of methyl substituents on the phen
ligands (Fig. 5), with the methylated complexes even displaying moderate activity against Gram-negative bacteria
[90]. The antimicrobial activity of ruthenium(II) polypyridyl
complexes containing phen ligands has attracted significant
attention more recently [91]. In a series of papers Keene and
Grant, et al. have reported the antibacterial activities of a
range of lipophilic mono-, bi-, tri- and tetra-nuclear Ru-phen
complexes (Fig. 6) [92-97]. Based on their own experience
and the evidence in the literature they concluded that the
development of mononuclear polypyridylruthenium(II) complexes as antimicrobials was limited due to their comparatively high MIC values when compared with that of state-ofthe-art antibiotics [91]. Although the mode of anti-bacterial
action of these ruthenium(II) complexes is not fully understood, DNA is considered to be their main target for biocidal
activity.
With the aim to develop better antimicrobials, Keene and
Grant, et al. elected to design dinuclear and higher nuclearity, enantiomeric, Rubbn, Rubbn-tri, Rubbn-tetra complexes,
incorporating the lipophilic bbn ligands (bbn = bis[4(4′methyl-2,2′-bipyridyl)]-1, n-alkane; n = 2,5,7,10,12,14 or 16)
(Fig. 6) [92]. Interestingly, the dinuclear complexes containing the short linking chains (bb2 and bb5) displayed very
poor activity against the range of bacterial strains tested [92].
The more lipophilic Rubbn complexes (where n >5) exhibited very good activity against Gram-positive and Gramnegative strains (MIC = 1-16 µg/ml), and preliminary toxicity studies indicated that the complexes were significantly
less toxic to eukaryotic cells (IC50= >78 µg/ml). Further-
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These workers also examined the anti-bacterial activity
of the tri- and tetra-nuclear complexes, Rubbn-tri and Rubbntetra (Fig. 7) [94]. All of the tri- and tetra-nuclear complexes
exhibited good antibacterial activity with the highly lipophilic linear complexes Rubb12-tri, Rubb16-tri, Rubb12-tetra
and Rubb16-tetra displaying the most activity, up to four
times more active than their dinuclear counterparts. Ironically, the trinuclear complexes were the most lipophilic but
the tetra-nuclear complexes were generally more active.
Generation of non-linear tetra-nuclear variants yielded complexes that were slightly more lipophilic but they were consistently less active when compared to their linear counterparts [93]. The level of cellular uptake of the Rubbn-tri and
Rubbn-tetra complexes was similar in both Gram-positive
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more, these Rubbn complexes were also very active against
drug-resistant strains such as MRSA and VRE, with the
Rubbn complexes with the more lipophilic longer linking
aliphatic chains (Rubb12, Rubb14 and Rubb16) exhibiting the
greatest activity (MIC = 1-4 µg/ml) [92]. Only slight differences in the anti-bacterial activity were observed between
the enantiomeric forms of the complexes. The results of cellular uptake studies correlated well with the activity profiles
of these complexes, with the uptake following a similar trend
(Rubb12 < Rubb14 < Rubb16; with LogP = -3.4, -2.7 and -1.9,
respectively), a trend not observed for the mononuclear
complexes, -[Ru(Phen)(bb7)]2+ and -[Ru(Me4Phen)3]2+ (Fig.
6) [95]. Furthermore, the uptake in Gram-negative bacteria
was significantly less when compared to that of the Grampositive species [95]. The dinuclear Rubbn complexes enter
bacteria in an energy-dependent manner and they significantly permeabilise the cell membranes [96], and interestingly the most active compound, Rubb16, preferentially binds
RNA and accumulates at the ribosomes in the bacteria [97].
These workers also showed that cellular uptake of the Rubbn
complexes could be significantly increased by including labile chloride groups on each metal centre but the resulting
Cl- Rubbn complexes were found to be less active than their
Rubbn counterparts [93]. Furthermore, the activity of the
dinuclear complexes against eukaryotic cells varies depending on the lipophilic nature of the Rubbn ligand offering the
possibility of making this class of complexes selective for
bacteria [98].
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Fig. (5). (a) Structure of tris(phen)ruthenium(II) cation [Ru(phen)3]2+ and (b) structure of tris(3,4,7,8-tetramethyl-phen)ruthenium(II) cation,
[Ru(3,4,7,8-Me4phen)3]2+.
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Fig. (6). Structure of [Ru(phen)2(bbn)] , Rubbn, [Ru(3,4,7,8-Me4phen)3]2+, Rubbn-tri and Rubbn-tetra complexes.

and Gram-negative species, the complexes were considerably less active against the Gram-negative bacteria, an observation that the authors attributed to the fact that some Gramnegative bacteria, particularly P. aeruginosa, may have inherent resistance to inert polypyridyl ruthenium complexes
[91].
In 2015, Keene and Collins et al. also reported the anti-P.
aeruginosa (ATCC 27853) activities of the geometric isomeric complexes cis-α-[Ru(Phen)(bbn]2+ and cis-β[Ru(Phen)(bbn]2+ (n = 10 or 12) (Fig. 7) [99]. Whereas all of
the [Ru(Phen)(bbn]2+ complexes displayed excellent activity
against the Gram-positive S. aureus, only the cis-α[Ru(Phen)(bb12]2+ exhibited activity against Gram-negative
species (E. coli and P. aeruginosa; MIC = 8 µg/ml for each
species), with its activity being two to four times that of its
isomeric form, cis-β-[Ru(Phen)(bb12]2+. Both cis-α[Ru(Phen)(bb12]2+ and cis-β-[Ru(Phen)(bb12]2+ readily accumulate in the two bacteria, but significantly they displayed
a much higher level of uptake in the P. aeruginosa.
They also compared the activity and uptake profiles of
the cis-α-[Ru(Phen)(bb12]2+ and cis-β-[Ru(Phen)(bb12]2+ with
those of the previously studied mononuclear complexes

[Ru(Me4Phen)3]2+ and [Ru(Phen)2(bb7]2+ (Fig. 6) and concluded that the structural differences between the complexes
are significant in terms of the interactions with the outer
membrane of P. aeruginosa. They also postulated that it may
be possible to modify this class of ruthenium complex to
modulate their cell membrane interactive capabilities and
essentially customize ruthenium complexes for activity
against specific Gram-negative bacteria.
In 2015, Wang et al. reported the anti-bacterial activity of
the
mononuclear
ruthenium
complex
cation,
[Ru(Phen)2(tip)]2+ (Fig. 8) [100]. [Ru(Phen)2(tip)]2+ exhibited significant activity against Gram-positive (S. aureus)
and Gram-negative (E. coli) bacteria (33% and 42% reduction in cell viability at 5µM concentrations, respectively).
Cellular uptake studies on this complex indicated that there
was 2-3 time more accumulation of [Ru(Phen)2(tip)]2+ in S.
aureus than in E. coli. SEM and AFM observations on the
morphology of the two bacteria indicated that contact with
[Ru(Phen)2(tip)]2+ caused cell membrane disruption and cytoplasm leakage, and agarose gel electrophoresis studies indicated that DNA and RNA damage were also key aspects of
the anti-bacterial mechanism of action of [Ru(Phen)2(tip)]2+.
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In 1982, Smit et al. reported evidence that the enzyme
inhibitory action of [Cu1(2,9-dimethyl-1,10-phenanthroline)2]NO3, associated with its antibacterial capability, is a
consequence of the toxicity of free copper ions and not that
of the phenanthroline ligand [101]. They observed, using
uptake studies with radiolabled 67Cu and [14C] 2,9-dimethyl1,10-phenanthroline, that significantly more copper than the
2,9-dimethyl-1,10-phenanthroline accumulated in the cell
wall of Mycoplasma gallisepticum cells. They concluded that
the [Cu1(2,9-dimethyl-1,10-phenanthroline)2]+1 dissociated
shortly after interaction with the cell membrane, that the
copper ions were transported into the cytoplasm, and that the
main function of the 2,9-dimethyl-1,10-phenanthroline appeared to be as a transport vehicle for the copper. The positive charge of the Cu2+ ion renders it hydrophilic and in nature uptake of copper ions relies on the presence of copper
transporter proteins [102]. Such abnormal elevation of intracellular copper, in the presence of membrane-permeable
phen ligands, has become well established [101].
More Li et al. have recently reported the antibacterial activity of the series of mixed amino acid/phen copper(II)
complexes,
[Cu(phen)(L-Ser)(H2O)Cl],
[Cu(phen)
(Gly)(H2O)]Cl, [Cu(phen)(L-Ala)(H2O)]Cl, [Cu(phen)(LPhe)(H2O)]Cl and [Cu(phen)2Cl2] and CuCl2 against E. coli
[103, 104]. These workers showed that the presence of the
lipophilic phen ligand in the complexes (which presumably
dissociate into [Cu(phen)(amino acid)]+ cations) can cause
an elevation in the levels of intracellular copper when com-

pared to the CuCl2 salt. Furthermore, they found that the bisphen complex, [Cu(phen)2]2+, caused the greatest accumulation of intracellular copper in the bacterium and when compared to the antibacterial activities of the CuCl2 (IC50 = 120
µg/ml) and the [Cu(phen)(amino acid)]+ complexes (IC50
range = 24.3 - 31.4 µg/ml) it was found to be more active
(IC50 = 7.5 µg/ml). They also showed that the acellular DNA
binding and cleaving capabilities of this series of compounds
and the copper salt followed the order [Cu(phen)2]2+ >
[Cu(phen)(amino acid)]+ >> CuCl2. Interestingly, they also
observed that all of the complexes could stimulate the
growth of the E. coli at lower concentrations. The three
[Cu(phen)(amino acid)]+ complexes, at a concentration of 16
µg/ml, enhanced growth by 17.61- 40.85%, [Cu(phen)2]2+ at
concentrations < 5 µg/ml stimulated growth by approximately 10%, and the copper salt CuCl2 had only a slight effect on growth of E. coli at low concentrations. The conclusion was that the presence of phen in the complexes increased their lipophilicity, improved the transport of copper
into the cells, causing excessive intracellular accumulation of
copper, and that the higher ratio of Cu: phen in [Cu(phen)2]2+
could explain its superior ability to induce the elevation of
copper levels. Zou et al. also reported that phen ligands can
cause abnormal elevation of intracellular copper [105].
In 2012, Aldrich-Wright et al. reported the results of a
preliminary anti-bacterial structure-activity study of a series
copper(II) and paladium(II) cationic complexes with the
general formulae, [Cu(IL)(A L)(H2O)]2+ and [Pd(IL)(AL)]2+
(where I L represents phen or 4-, 5-methylated or 4,7-, and
5,6-dimethylated 1,10-phenanthrolines, and A L represents
1,2-diaminoethane, 1S, 2S- or 1R,2R-diaminocyclohexane)
[106]. The palladium(II) complexes displayed only minimal
antibacterial activity, and whereas none of the complexes
were active against P. aeruginosa the copper(II) complexes
exhibited significant bactericidal activity against B. subtilis,
S. aureus and E. coli (MIC ranges: 8-64 µg/ml; 8-32 µg/ml;
8-32 µg/ml, respectively).
These workers extended this study by examining the antibacterial activities (S. aureus, E. coli and P. aeruginosa) of
a series of complexes, [M(IL)(AL)]2+ (where M = Cu or Pt;
where IL represents phen or 4-, 5-methyl, 4,7-, and 5,6dimethyl-, 3,4,7,8-tetramethyl-, 5-chloro-, 3,8-dibromo-, 5nitro- and 4,7-diphenyl- 1,10-phenanthrolines, and AL repre-
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sents
1,2-diaminoethane,
1S,
2Sor
1R,2Rdiaminocyclohexane) (Fig. 9) [75]. Phen and the majority of
the methylated-phen free ligands exhibited antibacterial activity with MIC values in excess of 20 µM. The exception
was the 4,7-diphenyl-1,10-phenanthroline which had superior activity against S. aureus and E. coli (MIC’s = 5-10 and
10-20 µM, respectively). With the exception of the complexes containing the 5-nitro-phen ligands, the copper complexes were most active against S. aureus, and where they
contained the methyl-, chloro-, bromo-, and 4,7-phenylfunctionalized phen ligands they exhibited a significant increase in activity when compared to their unsubstituted phen
containing analogues. In this series the most active complexes were the complexes containing the 3,4,7,8tetramethyl- and 4,7-diphenyl- substituted phen ligands
(MIC’s = 1.25-2.5 µM). No significant differences were observed between the RR- and SS- enantiomers of the copper
complexes. The platinum(II) complexes were found to be
selective for E. coli. (Growth Inhibition GI50 = 10-20 µM),
with no discernible added value accruing from replacing the
unsubstituted phen with the 4- and 5-methyl, 4,7-, and 5,6dimethyl- and , 5-chloro- functionalized phens. The complexes containing the 3,4,7,8-tetramethyl-phen ligand had
the lowest activity against E. coli (GI50 > 20 µM). Furthermore, the mono-, di- and tetra-methylated phen derivatives
exhibited decreasing anti-E. coli activity in that order, which
is in contrast to the activity observed for the free ligands
themselves.
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Fig. (9). The general structure of copper(II) and platinum(II) metal
complexes where M = Cu or Pt. * Indicates a chiral centre, R3-8
represent functionalised positions [75].

To probe the different activity profiles of the copper(II)
and platinum(II) complexes further these workers examined
the cell membrane permeabilisation capabilities (over a short
period - 25 mins) of the four most active complexes,
[Cu(4,7-diphenyl-phen)(AL)]2+ and [Pt(phen)(A L)]2+ (where
AL = 1S, 2S- and 1R,2R-diaminocyclohexane). The results
suggested that the two copper complexes exert a substantial
degree of membrane permeabilisation to S. aureus cells, possibly due to interaction with teichoic acid as a target. In contrast the platinum complexes did not exhibit significant disruption to E. coli membrane integrity. Interestingly, in a later
report these worker showed that the [Cu(IL)(AL)]2+ complexes (where IL represents phen or 5-methyl, 5,6-dimethyl-,

Viganor et al.

3,4,7,8-tetramethyl- and 4,7-diphenyl-phen) did not induce
lyses in red blood cells, and called into question their cell
membrane activity [107]. These workers attribute the lack of
activity of the copper and platinum complexes against P.
aeruginosa to reduced cellular uptake due to its lack of cell
membrane permeability (8% of that of E. coli) and the possible role of efflux mechanisms, provided by transport proteins
associated with the ‘intrinsic’ antibiotic resistance of this
microbe.
It is further postulated that compared to the stable platinum complexes that the copper complexes, [Cu(IL)(A L)]2+,
are labile and that their speciation products in solution are
likely responsible for the variation in their mode of action. It
is also proposed that their antibacterial activity is not simply
a sum of their components (metals and ligands), noting that
the mono-phen complexes such as [Cu(5,6-dimethylphen)(AL)]2+ are slightly more active against S. aureus (MIC
= 2.5-5.0 µM) than bis-phen complex such as [Cu(5,6dimethyl-phen)2]2+, reported earlier by Dwyer et al. (MIC =
4.0-7.9 µM) [43]. Furthermore, the metal-free phen and the
majority of its functionalised derivatives were reported to
primarily affect Gram-negative bacteria and upon coordination in the [Cu(IL)(AL)]2+ complexes results in a reduction in
activity against the Gram-negative species and an increase in
activity against S. aureus. These workers suggest that the
stable platinum complexes may be entering the E. coli cells
through an, as yet, unknown mechanism.
DNA AS AN ANTIBACTERIAL
METAL-PHEN COMPLEXES

TARGET FOR

DNA offers an interesting, underexplored, target for potential antimicrobials, and this is an approach currently attracting significant attention [108]. In 1979 Sigman et al.
reported the oxidative DNA cleavage capability of
[Cu(phen)2]2+ in the presence of a reductant [109]. Since this
discovery many metal complexes containing phen ligands
have been reported to interact and cleave DNA, with the
phen ligands increasing the intercalative properties of the
complexes.
Several groups have reported the antibacterial activity of
ternary metal(II)-phen complexes (metal = Cu2+, Ni2+, Co2+,
Mn2+) containing known quinolone/fluoroquinolone antibiotics [110-130]. The structural features and the broad biological activity of such complexes containing Cu2+, Ni2+, Co2+
and Zn2+ have been described in a recent review [131]. The
quinolone’s are synthetic antibacterial agents which target
the DNA-replication enzyme gyrase (type II topoisomerases)
and topisomerase IV [132]. Upon formation of binary complexes with metals such as copper(II) the ability of quinolones, such as iomefloxacin (Fig. 10), to bind DNA is significantly increased, but the complexes are not stable at
physiological pH [131]. The addition of phen to
[Cu(quinolone)]2+ yields very stable ternary complexes (Fig.
10), which are capable of binding DNA in an intercalative
mode, are nuclease active, and possess a cellular uptake
route different to that of the free quinolone drugs [128-130].
Furthermore, the use of a mutant strain of E. coli, devoid of
porins, proteins responsible for the filtration of hydrophilic
compounds in Gram-negative bacteria [76], have shown that
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Fig. (10). The structure of lomefloxacin and its ternary copper(II) complex with phen [Cu(lomefloxacin)(NO3(phen)].

[Cu(quinolone)(phen)]2+-type complexes are hydrophobic
and that they enter the cells in a porin-dependent manner
[130]. Similar DNA binding and/or nuclease capabilities
have been implicated in the antibacterial mechanism of action of a range of similar mono-phen complexes containing
non-quinolone donor ligands and metal centres such as Ag1+
[133], Cu1+[134, 135], , Cu2+[114, 116, 136-141], Co2+[136,
137], Ni2+[142], Co3+[143], Mn3+[144], Pd2+ [116], Pt2+ [75],
Fe3+[145] and Zn2+ [146]. Furthermore, several cationic bisphen complexes with the general formula [ML(phen)2]2+ ( M
= Cu2+, Zn2+, Ni2+,Y3+ Pd2+ and Dy3+) have also been reported to bind/cleave DNA and they exhibit clinically relevant antibacterial activity against Gram positive and Gram
negative bacteria [116, 147-152]. Cationic Cu(phen)2+ and
Cu(phen)22+ moieties have also been incorporated into polymeric conjugates, which are also capable of binding and
cleaving DNA and which also exhibit clinically relevant antibacterial activity against Gram positive and Gram negative
bacteria [153, 154].
The ruthenium(II) polypyridyl complexes are well known
for their ability to interact with DNA [155]. Keene and Grant
et al. have reported the antibacterial activities of a range of
lipophilic mono-, bi-, tri- and tetra-nuclear Ru-phen complexes (Fig. 6 and Fig. 7) [92-99], and they attribute their
biological activities to their ability to interact and damage
DNA. Indeed the dinuclear complex, [{Ru(Phen)2} (µbb7)]2+ has been shown to bind chromosomal DNA from S.
aureus [96]. Aldrich-Wright et al. explored the antibacterial
activity of the mononuclear ruthenium complexes, [Ru(2,9dimethyl-phen)2(IL)]2+ (IL = a strong intercalating ligand such
as dppz) (Fig. 11), which have proven DNA binding capabilities [156]. These workers found that there was a direct
correlation between the antimicrobial activity profile of the
complexes and the affinity of the intercalating ligands for
DNA, and they concluded that the observation was consistent with a mode of action involving DNA-binding.
Although many metal complexes containing phen ligands
have been shown to bind DNA it should be noted that this
property does not necessarily bestow antibacterial capability
on them. Reedijk and Wezel et al. have recently reported the
platinum chloride complexes, [Pt(phendione)Cl2] and
[Pt(dppz)Cl2] (Fig. 12), which can intercalate DNA and ex-

hibit significant in vitro anticancer activity, but which are
inactive against bacteria [60]. Starosta et al. reported the
anti-S. aureus activity and plasmid DNA cleaving capabilities of a series of cuprous iodide complexes incorporating
phen or 2,9-dimethyl-phen with three different
tris(aminomethyl)phosphane ligands (Fig. 13) [134]. They
found that the complexes with the highest antibacterial activity exhibited the weakest ability to cleave the plasmid DNA.
Chetna et al., tested the DNA nuclease and antibacterial activities of the four binuclear copper(II) complexes,
[Cu(oxpn)Cu(N-N)]2+ (where oxpn = N,N′-bis[3(methylamino)propyl] oxamide; N-N = bipy or phen or dpq
or dppz) (Fig. 14) [140]. Although the DNA cleaving capability was in the order of [Cu(oxpn)Cu(dppz)]2+ >
[Cu(oxpn)Cu(dqp)]2+
>
[Cu(oxpn)Cu(phen)]2+
>
2+
[Cu(oxpn)Cu(bipy)] only the bipy containing complex exhibited appreciable antibacterial activity against the Gramnegative E. coli. (MIC = 20 µg/ml). In our laboratory we
have recently reported the in-vitro antibacterial activity of
the water-soluble silver complex, [Ag2(phen)3(udda)] (uddaH2 = undecanedioic acid) (Fig. 15) [157].
[Ag2(phen)3(udda)] displays appreciable activity against E.
coli (IC50 = 9.54 µM), S. aureus (IC50 = 14.18 µM), and P.
aeruginosa (IC50 = 32.47 µM), and it is cytotoxic towards
cisplatin-sensitive breast (MCF-7) and resistant ovarian
(SKOV-3) cancer cell lines. It is an avid DNA binder with
intercalative capability greater than that of the standard
ethidium bromide, and yet it appeared to be incapable of
inducing DNA damage in mammalian cells.
Zhao et al. have reported the DNA binding and antibacterial activities of the neutral ternary lanthanide complexes,
[RE(sal)3(phen)] and [RE(cin)3(phen)] (RE = La3+, Pr3+,
Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Tm3+, Yb3+, Lu3+ ;
salH = salicylic acid; cinH = cinnamic acid) [158, 159]. The
complexes all bind to DNA in an intercalative mode and the
strength of the binding is indirectly proportional to the size
of the radius of the lanthanide cation in the complexes. Furthermore, these workers found that the complexes displayed
antibacterial activity against E. coli comparable to that of the
free phen ligands, and that the activity followed the same
trend as the binding capabilities of the complexes, with the
complexes of the heavier metals more active than those containing the smaller lanthanides.
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Photocleavage of DNA
A number of papers have been reported in the literature
that describes antibacterial active phen–based complexes that
cleave DNA when irradiated with light. In 2015, Sudhamani
et al. reported that the copper complexes [Cu(mqt)(NN)H2O]1+ (mqt = 2-thiol-4-methylquinoline; N-N = phen,
dpq or dppz) (Fig. 16) bind DNA in a groove binding mode
and that they exhibit photonuclease capability with the

photo-cleavage ability following the same order as the binding strengths of the three complexes, [Cu(mqt)(dppz)H2O]1+
> [Cu(mqt)(dpq)H2O]1+ > [Cu(mqt)(phen)H2O]1+ [160].
Mechanistic studies revealed the involvement of singlet oxygen (1O2) in the photo-cleavage process, the three complexes
exhibited potential in photodynamic antimicrobial chemotherapy (PACT) as they were also found to kill E. coli upon
photo-irradiation by a tungsten-halogen 500W lamp. N.
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Raman et al. have reported the DNA binding and photonuclease capability of the bis-phen copper(II) complexes
[Cu(dbdppo)(phen)2]2+ and [Cu(hnbdppo)(phen)2]2+ {dbdppo
= (4-(3′,4′-dimethoxybenzaldehyde)2-3-dimethyl-1-phenyl3-pyrazolin-5-one; hnbdppo = (4- (3′-hydroxy-4′nitrobenzaldehyde)2-3-dimethyl-1-phenyl-3-pyrazolin-5one}[161]. The DNA cleavage reaction was found to be mediated by hydroxyl radicals generated by a photo-redox
mechanism. The complexes were found to exhibit significant
antibacterial activity but their PACT potential under photoirradiation was not investigated. Similarly, a number of other
papers describe the photonuclease capability of bis-phenbased complexes with Co3+ [162-165] and Ru2+ [165-168],
along with their antibacterial capabilities, independent of any
PACT-type studies. In 2014, Frei et al. reported the results
of a study on the PACT potential of the known stable neutral
bis-phen ruthenium complex, [Ru(DIP)2(bdt)] (DIP = 4,7diphenyl-phen; bdt = 1,2-benzenedithiolate) (Fig. 17) [169].
The phototoxicity of [Ru(DIP)2(bdt)] was found to be considerably superior to the clinically approved photosensitizers
porfimer sodium and 5-aminolevulinic acid, and the complex
was efficient at killing Gram-positive bacteria. The DNA
binding capabilities and the photochemical properties offered
by metal complexes containing phen ligands presents sig-

nificant potential to contribute to the development of PACT.
PACT is a relatively new avenue of research which offers an
effective alternative approach in the era of antibiotic resistance, whereby DNA is only one target, which can be exploited in tandem with a number of other targets to deliver a
multimodal therapeutic approach for which bacterial resistance has proved difficult [170].
INDUCTION OF OXIDATIVE STRESS
It has recently been shown that some bactericidal antibiotics induce microbial cell death by stimulating the production of destructive ROS, which can activate cellular respiration, causing superoxide production and the liberation of iron
ions from iron-sulphur proteins [171-174] which, in turn,
catalyses hydroxyl radical formation via Fenton chemistry.
These HO. radicals can induce microbial cell death by oxidising proteins, lipids and DNA, [172-175] and can ultimately trigger mutations which promote antibiotic resistance
[176]. In defence, bacteria respond to ROS by deploying
antioxidant enzymes (e.g. superoxide dismutase and catalase) [175] and small antioxidant molecules like ascorbic
acid and glutathione [177]. Additionally, microbially produced nitric oxide [178] and hydrogen sulphide [179] gas
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molecules can each impede Fenton chemistry and promote
antibiotic tolerance. There is also evidence to show that, under conditions of nutrient deprivation, some bacteria can
endure antibiotics due to the limited manufacture of prooxidant metabolites and an increase in their antioxidant defences [180].

N
N

N
Ru

O2S

N
SO2

Fig. (17). Structure of [Ru(DIP)2(bdt)].

Metal-phen complexes such as [Cr(phen)3]3+ are known
to generate ROS in bacteria, contributing to their antimicrobial activity [181]. The use of metal-phen-based photo sensitizers in PACT also offers the potential to generate free radicals in bacteria leading to oxidative lethal damage and/or
apoptosis [169]. It has been shown that upon the addition of
hydrogen peroxide, the antibacterial activity of metal-free
phen is significantly enhanced against E. coli [182]. It was
concluded that the Fenton reaction, which generates highly
cytotoxic hydroxyl and perhydroxyl free radicals, could potentially be catalysed through the in vivo formation of
Fe3+/Fe2+-phen adducts. Furtado et al. later further examined
this proposed pathway by repeating the exposure of E. coli to
both phen and H2O2 in the presence of known Fe2+ and Fe3+
scavengers and, separately, in the presence of the free-radical
scavenger, thiourea [183]. Interestingly, protection was
achieved for the radical and Fe2+ scavengers (bipyridine,
bipy), rather than the Fe3+ scavenger (desferal). It is noteworthy that these workers also found that neocuproine (2,9dimethyl-phen, Fig. 4), a known Cu1+ scavenger, also offered
significant protection, supporting the notion that the known
metallo-nuclease, [Cu(phen)2]1+, can play a role in bacterial
cytotoxicity.
INHIBITION OF ENZYMES
According to the study of Zhu et al. in 2013, methyltransferase (MeTrCd) and acetyl-coenzyme A synthase
(ACSCd) are two key enzymes in the acetylcoenzyme A
synthesis pathway of the human pathogen Clostridium difficile, which is absent in humans and essential for the survival
of the pathogen [184]. Screening inhibitors of the enzymes,
the group has shown excellent inhibition effect of phen on
ACSCd methyl group transfer and acetyl-coenzyme A synthesis activity at 1 mM concentration. This inhibitory effect
was further examined by checking the antibacterial activity
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of the inhibitor against C. difficile and, phen had an inhibitory effect on the pathogen at 25 mM. This study suggests
that 1,10-phenantrholine targets and inhibits these key enzymes interfering with the pathogen survival pathway.
In 2009, Sharma et al. reported that the bacterial peptide
deformylase (PDF) catalyses the removal of the N-terminal
formyl group of proteins and it is essential for protein maturation, growth and survival of bacteria [185]. Thus PDF became a very attractive antimycobacterial drug target. In this
study, various well-known PDF inhibitors, such as BB-3497,
actinonin, 1,10-phenanthroline, hydroxylamine hydrochloride and galardin, were selected to evaluate their inhibitory
activity against Mycobacterium tuberculosis. All compounds
were active against M. tuberculosis, displaying a bacteriostatic mode of inhibition (MIC9 values ranging from 0.274 mg/L), but BB-3497 and 1,10-phenanthroline exhibited
the most potent in vitro antimycobacterial activity with
MIC’s of 0.25 and 0.8 mg/L, respectively, suggesting the
potential of these promising PDF inhibitors against M. tuberculosis.
In a study by Upadhye et al., in 2009 the effects of serine, a metalloprotease inhibitor, have been evaluated on mycobacterial ES-31 serine protease, to assess the importance
of this enzyme for bacterial cell growth [186]. 1,10phenanthroline was tested and at a concentration of 0.5 mM
it inhibited 78% of mycobacterial ES-31 serine protease activity in vitro. 1,10-phenanthroline also showed a decreased
bacterial growth in 61% in axenic culture at 0.1mM and the
inhibition was further confirmed by a decreased amount in
73% of ES-31 serine protease secreted in the culture filtrate.
In human macrophage culture, 1,10-phenanthroline inhibited
the infectivity of virulent and avirulent M. tuberculosis bacilli to macrophages by 68% and 63% growth inhibition of
each respectively. It was observed that addition of mycobacterial ES-31 serine protease to macrophage culture enhanced
the entry of bacilli and their multiplication in human macrophages, however, the addition of 1,10-phenanthroline
strongly inhibited the mycobacterial growth as observed by
decreased CFU count, showing the importance of mycobacterial ES-31 serine protease for pathogen infectivity.
In their pioneering work Dwyer et al. identified the enzyme inhibitory activity of polypyridyl metal complexes
when they found that they could deactivate acetylcholinesterases [90], opening up the possibility of developing
phen-based complexes that target enzymes in bacteria. In
2013, Tarushi and co-workers reported the antimicrobial
activities of Zn(II) complexes with the general formula
[Zn(quinolone)(phen)Cl] (quinolone = flumequine, oxolinic
acid and enrofloxacin) [187]. The group reported that all
complexes possessed a potent antibacterial activity against B.
subtilis, B. cereus, S. aureus and E. coli, exhibiting very low
MIC values in the range and 2–10 µg/mL. The complexes
were also found to interact DNA in an intercalative binding
mode, but their antibacterial activity was also attributed to
their ability to inhibit DNA replication by targeting essential
type II bacterial topoisomerases such as DNA gyrase and
topoisomerase IV.
Recently, the antibacterial activities and the alkaline
phosphatase (ALP) inhibitory capability of the metal-free
phen and the ternary copper(II) complexes, [Cu(phen)
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(meimzH)(H2O)2]2+
and
[Cu(phen)(cnge)(H2O)(NO3)2
(meimzH = methylimidazol; cnge = cyanoguanidine) were
examined [141, 188]. It was demonstrated that metal-free
phen was an effective inhibitor of ALP and it was postulated
that the mode of action was associated with the sequestration
of Zn2+ ions from the active site of the enzyme. The two
phen-based complexes, [Cu(phen)(cnge)(H2O)(NO3)2] and
[Cu(phen)(meimzH)(H2O)2]2+ were also reported to exhibit
an inhibitory effect with their mode of action attributed to a
ligand-substitution mechanism involving the ALP protein.

mg/kg or 10 mg/kg doses). Although 100% of mice were
moribund following 2 days of infection, treatment groups
likewise survived significantly better, suggesting that 5nitro-phen has a modest effect on C. difficile infection in
vivo.
There are very few reports in the literature describing the
anti-biofilm activity of phen-based complexes. In 2016, Viganor et al. also reported the antibacterial activity of phendione against P. aeruginosa and its biofilm, [190]. The phendione was found to be significantly more active against the
pathogen than the parent phen (MIC90 = 12.50 µg/ml and
200 µg/ml against susceptible and resistant isolates, respectively) Furthermore, pretreatment of the bacteria with phen,
phendione and the Cu2+ and Ag1+ complexes,
[Cu(phendione)3]2+ and [Ag(phendione)3]+ (Fig. 18), at 0.5 x
MIC values inhibited biofilm formation. [Cu(phendione)3]2+
and [Ag(phendione)3]+ were particularly active, reducing
both biomass (by 48% and 44%, respectively) and viability
(by 78% and 77%, respectively). Furthermore, phen, phendione, [Cu(phendione)3]2+ and [Ag(phendione)3]+ also disrupted mature biofilm, in a dose dependent manner, with the
metal complexes being particularly active (IC50 = 9.39 µM
and 10.16 µM, respectively). These results are particularly
significant given the resistance issues associated with P.
aeruginosa which is a pathogen typically isolated from
nosocomial infections, which is emerging as a particular
global healthcare problem as the emergence of MDR isolates
of this species is limiting the number of effective antimicrobials that are available to treat infected patients [190-193].

ACTIVITY OF METAL-PHEN COMPLEXES ON
BIOFILMS
1,10-phenanthroline-5,6-dione (phendione) (Fig. 4), has
been shown to be active against Enterococcus, with the ability to eradicate E. faecalis biofilms, and its activity appears
to be related to its ability to sequester Zn2+ ions from metallo-enzymes [28]. The authors did not know exactly how
phendione eradicated the E. faecalis biofilm, but they speculated that phendione may weaken the extracellular polymeric
substances of the biofilm by disrupting the Zn2+ balance, and
allowing the compound to get into bacterial cells harbored
deep within the biofilm to exert its antimicrobial effects as a
metalloprotease inhibitor. In 2014 Katzianer et al. reported
the results of the antimicrobial activity of 5-nitro-phen
against Clostridium difficile [189]. 5-nitro-phen showed potent bactericidal effects in vitro and it was shown to inhibit
the growth of all three tested C. difficile strains efficiently
(MIC ≈2 µM) at concentrations comparable with the firstline drug metronidazole. In the same study, 5-nitro-phen
promoted C. difficile biofilm dispersal. For this assay,
biofilm associated cells of C. difficile were incubated with
the compound for different times and the remaining biofilm
was quantified by crystal violet staining. The biofilmassociated biomass was significantly reduced in tests involving 6 h and 24 h exposures, suggesting that 5-nitro-phen may
promote C. difficile biofilm dissolution. Additionally, the
group examined the efficacy of 5-nitro-phen in a murine
model and the compound displayed modest in vivo effects
against C. difficile infection. For this test, mice were infected
with C. difficile and were treated with the compound (5
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fold the MIC) was required to get an appreciable reduction
(approximately 44%) in the biomass in the S. aureus biofilm,
whereas for example 25 µg/ml of [Cu(5,6-dimethylphen)(SS-dach)]2+ (equivalent to 3 fold the MIC) rapidly (2
h) reduced the biofilm by 68%. All of the copper complexes
had similar activity against the biofilm. Replacing the Cu2+
in [Cu(5,6-dimethyl-phen)(SS-dach)]2+ with Pt2+ and Pd2+
significantly reduces the antibacterial and anti-biofilm activities. It was suggested that the nuclease capability of the copper complexes (which is not a feature of the platinum and
palladium complexes) may be a significant factor in their
mechanism of action against both planktonic and biofilm
growing cells, particularly given that the extracellular matrix
of biofilms are known to contain significant levels of nucleic
acids.
CONCLUDING REMARKS
Bacterial resistance to antibiotics now represents one of
the greatest challenges to public health, globally. In an effort
to address the diminution of the therapeutic options in this
“era of resistance” there is a pressing need to identify antibacterial agents that can either target bacteria in ways that
are different to the current arsenal of antibiotics or that can
kill bacteria in a multimodal fashion, thereby preventing the
rapid onset of resistance. In the 1950’s, 1960’s and 1970’s
work, pioneered by Francis Dwyer, on the antibacterial activity of metal complexes containing 1,10-phenanthroline
ligands [90, 93], opened the door to the development of the
diverse biological profile of this class of inorganic compound [44]. These early results clearly demonstrated the antibacterial chemotherapeutic potential of metal complexes of
1,10-phenanthroline, but the significance of the results was
not embraced by the pharmaceutical sector as the “antibiotic
era” was at its height and antibiotic resistance was not appreciated as an insurmountable problem.
As we are now aware the “antibiotic era” has been characterized by the overuse and misuse of antibiotics, culminating in the present critical “era of resistance”. Consequently,
there has been a recent surge in interest in the antimicrobial
applications of metal-based compounds, with the application
of metal complexes incorporating 1,10-phenanthroline
ligands playing a significant role. 1,10-phenanthroline exerts
in vitro antimicrobial activity against a broad-spectrum of
bacteria, in its own right. The antimicrobial activity of 1,10phenanthroline can be significantly modulated by modifying
its structure. The development of metal-phen complexes affords the medicinal chemist an opportunity to exploit such
structural diversity by introducing a variety of metal centres,
offering the opportunity to control characteristics such as the
geometry, lipophilicity, redox status, ability to generate
beneficial reactive oxygen/nitrogen species and the ability to
interact with biomolecules such as DNA and proteins. Metal
complexes of phen-type ligands are generally more active
than the metal-free ligand and the efficacy of such complexes can be further improved by introducing auxiliary
ligands, such as the quinolones, which are themselves bioactive. The study of metal-phen complexes as potential antibacterials is in its infancy and although this review presents
an encouraging perspective with respect to the potential for
the deployment of such inorganic therapeutics in the fight
against bacteria the transfer of the results of the in vitro stud-
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ies into in vivo models remains largely unexplored. The toxicity profiles for phen and some metal-phen complexes in
nematode [106], insect larval [32], and animal [58] models
have been reported, with metal-free phen and some metalphen complexes displaying favorable tolerance levels. Since
Dwyer early reports of in vivo activity [64, 90] very few in
vivo bacterial infection studies have been carried out on phen
and its metal complexes. The complex, [Ru(2,9-dimethylphen)2(dppz)]2+ (Fig. 11), was recently shown to be active in
rescuing the soil nematode Rhabditis elegans post infection
with MRSA [156]. Data derived from appropriate in vivo
models are necessary to ensure that effective drug delivery,
low toxicity and optimal drug concentrations preventing bacterial cell proliferation can be achieved. DNA is assumed as
a key target for metal-phen-based antibacterials and to date
the vast majority of the data relating to this aspect of their
activity has been based on acellular assays. There is a need
to study the effects that the complexes are having on DNA in
a cellular context using biochemical and established cellbased spectroscopic techniques. Indeed, having researched
this topic it is clear that there is dearth of knowledge in relation to how metal-phen complexes are interacting with a
range of biomolecules within bacterial cells. Metal-phen
complexes are clearly multimodal in their mechanism and
there is a need to integrate what is currently known about the
mechanisms into an advanced systems biology approach
utilising novel ‘omics’ technologies with Bioinformatics.
‘Omics’ technologies involve global and high-throughput
analytical methods such as genomic microarrays, 2D-gel and
2DLC/MS proteomics or biochemical reactions of metabolites (metabolomics), ions (ionomics) or metals (metallomics). These Omics technologies are supported by advanced
Bioinformatic techniques and have been critical in providing
information on key mechanistic targets and cellular pathways for many pharmaceutical agents. Integrated online databases with molecular networking of ‘omics’ data reveals
relationships between novel complexes/drugs and functional
molecules thus providing a widened biological perspective
of the mechanisms of action. ‘Omics’ technologies are lesstime consuming and more efficient than traditional biochemical techniques and are being widely adopted by many
areas of biological and pharmaceutical research, however
there are many recognised challenges which include data
acquisition and analysis; modelling of multi-omics data sets
for a systems biology approach and moreover the experimental preservation of an in situ state of metal-phen complexes
in an already complex cellular system [194].
ABBREVIATIONS
AFM

= Atomic force microscopy

ALP

= Alkaline phosphatase

AMR

= Antimicrobial resistance

BLM

= Bleomycin

DNA

= Deoxyribonucleic acid

EPS

= Extracellular polysaccharides

ESBL

= Extended spectrum β-lactamases

ESKAPE = Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter bau-
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manii, Pseudomonas aeruginosa and Enterobacteriaceae
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[4]

GBS

= Group B Streptococcus

[5]

GI

= Growth inhibition

[6]

HGT

= Horizontal gene transfer

HUVECs = Human umbilical vein endothelial cells
MCF-7

= (Michigan Cancer Foundation) Human breast
adenocarcinoma cell line

[7]

MDR

= Multidrug resitance

[8]

MeTrCd = Methyltransferase
ACSCd

= Acetyl-coenzyme A synthase

MIC

= Minimum inhibitory concentration

MRSA

= Methicillin-resistant S. aureus

OmpC

= Outer membrane porin C

OmpF

= Outer membrane porin F

PACT

= Photodynamic antimicrobial chemotherapy

PDF

= Peptide deformylase

PHEN

= 1,10-phenanthroline

RNA

= Ribonucleic acid

ROS

= Reactive oxygen species

SEM

= Scanning electron microscopy

SKOV-3 = (Sloan Kettering) Human ovary adenocarcinoma cell line
SN

= Streptonigrin

QS

= Quorum sensing

VRE

= Vancomycin-resistant Enterococcus

XDR

= Extensively drug resistance
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